Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.

Patel L, Bernard LM, Elder GJ.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):232-44. doi: 10.2215/CJN.06800615. Epub 2015 Dec 14. Review.

2.

A Canadian cost-effectiveness analysis of transcatheter mitral valve repair with the MitraClip system in high surgical risk patients with significant mitral regurgitation.

Cameron HL, Bernard LM, Garmo VS, Hernandez JB, Asgar AW.

J Med Econ. 2014 Aug;17(8):599-615. doi: 10.3111/13696998.2014.923892. Epub 2014 May 30.

PMID:
24826880
3.

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.

Sung AD, Grima DT, Bernard LM, Brown S, Carrum G, Holmberg L, Horwitz ME, Liesveld JL, Kanda J, McClune B, Shaughnessy P, Tricot GJ, Chao NJ.

Bone Marrow Transplant. 2013 Nov;48(11):1444-9. doi: 10.1038/bmt.2013.80. Epub 2013 Jun 10.

4.

Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis.

Grima DT, Dunn ES, Bernard LM, Mendelssohn DC.

Curr Med Res Opin. 2013 Feb;29(2):109-15. doi: 10.1185/03007995.2012.756808. Epub 2012 Dec 20.

PMID:
23216385
5.

Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs.

Grima DT, Bernard LM, Dunn ES, McFarlane PA, Mendelssohn DC.

Pharmacoeconomics. 2012 Nov 1;30(11):981-9. doi: 10.2165/11599390-000000000-00000.

PMID:
22946789
6.

A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735.

Bernard LM, Verma S, Thompson MF, Chan BC, Mittmann N, Asma L, Jones SE.

Curr Oncol. 2011 Apr;18(2):67-75.

7.

Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada.

Attard CL, Maroun JA, Alloul K, Grima DT, Bernard LM.

Curr Oncol. 2010 Feb;17(1):17-24.

8.

Considerations in developing model-based economic evaluations of glaucoma treatment.

Althin R, Grima DT, Dhawan R, Bernard LM.

J Glaucoma. 2006 Dec;15(6):541-7.

PMID:
17106369
9.

Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension.

Tingey D, Bernard LM, Grima DT, Miller B, Lam A.

Can J Ophthalmol. 2005 Apr;40(2):161-9.

PMID:
16049529
10.

Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France.

Bernard LM, Althin R, Dhawan R, Grima DT, Lam A, Aballéa S.

Eur J Ophthalmol. 2003 Jul;13 Suppl 4:S30-43.

PMID:
12948051
11.

Aldose reductase activities in microdissected rat renal tubule segments.

Sands JM, Terada Y, Bernard LM, Knepper MA.

Am J Physiol. 1989 Apr;256(4 Pt 2):F563-9.

PMID:
2495737
12.

Ultrastructure and metabolism of skeletal muscle fibres in the tench: effects of long-term acclimation to hypoxia.

Johnston IA, Bernard LM.

Cell Tissue Res. 1982;227(1):179-99. No abstract available.

PMID:
7172208
13.

Supplemental Content

Loading ...
Support Center